Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary

Pulmonx reported Q3 2026 revenue of $22.84M, up 6.2% YoY, with net loss narrowing to $8.39M. EPS improved to ($0.19) from ($0.34). Growth driven by Zephyr Valve procedures, offset by lower U.S. volumes and paused China shipments. Nine-month revenue declined 2.5% to $66.2M. China shipments expected to resume in early 2027.

Original reporting
Published Nov 3, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary — source image
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

The disclosed numbers are the first public release of Q3 2026 performance, offering fresh data for valuation models.

02

Market read

Micro‑cap earnings release with modest revenue growth and loss narrowing; limited but immediate relevance for traders holding or shorting LUNG.

03

What to watch

Potential future upside from resumed China shipments in 2027 and ongoing clinical trial progress.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Pulmonx is a medical‑device company focused on lung‑related therapies. The 10‑Q filing provides its first quarterly financial snapshot for 2026.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

Pulmonx reported Q3 2026 revenue, net loss and EPS figures in its 10‑Q filing.

Expected impact

potential modest upside as the market prices in the loss narrowing

Evidence & confidence

The company remains loss‑making; the improvement is modest and limited to a micro‑cap, so price reaction is likely limited.

Market effects

Limited impact on the broader medical device sector; Pulmonx is a niche player.

No significant regional effect; results pertain to U.S. and limited international markets.

Minimal global relevance given the company's small size.

Counterpoint

Investors may view the continued loss as a red flag despite the narrowing gap.

Key entities

  • Pulmonx Corp

    Medical‑device firm reporting Q3 2026 results.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.